Update on New and Departing Alliance Board Members
by Eric Gray, Vice Chair

The mission of the Hemophilia Alliance is to work “to ensure member Hemophilia Treatment Centers have the expertise, resources and public support to sustain their integrated clinical and pharmacy services for individuals with bleeding and clotting disorders”. Per the Hemophilia Alliance by-laws, “The Board of Directors should, to the extent feasible, include members representative of the eight (8) regional networks of hemophilia treatment centers, types of programs, expertise, and experience.”

First, the Hemophilia Alliance would like to express its gratitude to the following departing directors:
Christine Guelcher RN-BC MS, PPCNP-BC served on the Alliance board with distinction, including serving as a mentor for Jeff Blake and Sean Singh. We congratulate Chris, who retired from Children’s National Medical in 2021. She has taken a position with Genentech serving as a Medical Science Liaison in the rare blood disorder division. We wish her all the best and know they are lucky to have her! We look forward to seeing her around in the coming years.

Stephanie Raymond has served on the Alliance board for the last five years. She also served as the Alliance representative on the Hemophilia Alliance Foundation Board. She made the tough decision to step down from these responsibilities while she leads Cascade through an expansion and move into a much larger facility. We are delighted we will have her ongoing support for the Alliance. Cascade as many of you know was one of the founding members of the Alliance.

We also want to sincerely thank all applicants for their interest in serving on the board. We thoughtfully reviewed and considered all applicants in the context of the Mission and by-laws, seeking to most broadly represent our membership as well as diversify our expertise and insight to most strategically address challenges to further our mission.

We are pleased to announce Zack Duffy, MPA and Dr. Michael Silvey have been elected to serve on the Board, with their terms beginning January 2022. Zack is the Program Administrator for the HTC at the Oregon Health and Science University. Zack brings expertise in operating a 340B program via both physician-dispense and on-site pharmacy models, payer and government relations and regulatory oversight. He has been actively involved with Pacific Northwest Bleeding Disorders and the Mountain States Hemophilia Network. Dr. Silvey is the Associate Professor of Pediatrics, Associate Director of the Kansas City Regional HTC, Children’s Mercy Hospital where he specializes in bleeding and clotting disorders. He has published original research and review articles in peer-reviewed journals and presents nationally and internationally on a number of bleeding and clotting disorder topics.

Again, we can’t thank enough the individuals who applied to serve on the board. We may be reaching out to you to assist in serving the Alliance in other ways.